Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FATE THERAPEUTICS, INC.

(FATE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2021 09/15/2021 09/16/2021 09/17/2021 09/20/2021 Date
64.81(c) 66.5(c) 66.51(c) 71.6(c) 67.2 Last
768 165 713 298 497 874 2 060 422 1 122 099 Volume
-1.47% +2.61% +0.02% +7.65% -6.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 43,6 M - -
Net income 2021 -209 M - -
Net cash position 2021 708 M - -
P/E ratio 2021 -32,1x
Yield 2021 -
Sales 2022 39,3 M - -
Net income 2022 -248 M - -
Net cash position 2022 519 M - -
P/E ratio 2022 -27,6x
Yield 2022 -
Capitalization 6 815 M 6 815 M -
EV / Sales 2021 140x
EV / Sales 2022 160x
Nbr of Employees 356
Free-Float 98,2%
More Financials
Company
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell... 
Sector
Biotechnology & Medical Research
Calendar
09/22 | 04:35pmPresentation
More about the company
Ratings of Fate Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about FATE THERAPEUTICS, INC.
09/15Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrati..
GL
09/15FATE THERAPEUTICS : Announces Publication of FT538 Preclinical Data Demonstratin..
AQ
09/15Fate Therapeutics, Inc. Announces Publication of FT538 Preclinical Data Demon..
CI
09/14INSIDER SELL : Fate Therapeutics
MT
09/02FATE THERAPEUTICS : to Present at Upcoming Investor Conferences
AQ
08/26FATE THERAPEUTICS : Morgan Stanley Starts Fate Therapeutics at Equal-Weight With..
MT
08/20FATE THERAPEUTICS : Shares Slump After Interim Trial Results for FT596, FT516 Ce..
MT
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20SECTOR UPDATE : Health Care
MT
08/19FATE THERAPEUTICS : Reports 'Positive' Interim Trial Results for FT596, FT516 Ce..
MT
08/19FATE THERAPEUTICS : Announces Positive Interim Clinical Data from its FT596 and ..
AQ
08/19Fate Therapeutics, Inc. Announces Positive Interim Clinical Data from its FT5..
CI
08/05Fate Therapeutics Appoints Yuan Xu to its Board of Directors
CI
08/05FATE THERAPEUTICS : SVB Leerink Adjusts Price Target on Fate Therapeutics to $11..
MT
08/04FATE THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Highlights..
PU
More news
News in other languages on FATE THERAPEUTICS, INC.
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal - BB Biotech erhöht Allokation..
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
2020BB Biotech im zweiten Quartal mit Milliardengewinn dank Biotech-Hype
2019Bayer mise sur les cellules souches avec le rachat de BlueRock
More news
Analyst Recommendations on FATE THERAPEUTICS, INC.
More recommendations
Chart FATE THERAPEUTICS, INC.
Duration : Period :
Fate Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FATE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 71,60 $
Average target price 109,67 $
Spread / Average Target 53,2%
EPS Revisions
Managers and Directors
J. Scott Wolchko President, Chief Executive Officer & Director
Edward J. Dulac Chief Financial Officer & Accounting Officer
William H. Rastetter Chairman
Wen Bo Wang Senior Vice President-Technical Operations
Bahram Valamehr Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
FATE THERAPEUTICS, INC.-21.26%6 815
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850